Atezolizumab Plus Bevacizumab and Chemotherapy Fails to Provide PFS Benefit in Platinum-Sensitive

September 13, 2023Kyle DohertyThe addition of the PD-L1 inhibitor atezolizumab to bevacizumab and platinum-based chemotherapy did not result in a statistically significant progression-free survival be

Updated on: October 11,2023 222

Atezolizumab Plus Bevacizumab and Chemotherapy Fails to Provide PFS Benefit in Platinum-Sensitive

September 13, 2023Kyle DohertyThe addition of the PD-L1 inhibitor atezolizumab to bevacizumab and platinum-based chemotherapy did not result in a statistically significant progression-free survival be

Updated on:October 11,2023 222

Perioperative Durvalumab Plus Chemo Yields Responses, EFS Benefit in Resectable NSCLC

September 11, 2023Kyle DohertyThe addition of perioperative durvalumab to neoadjuvant chemotherapy led to a significant improvement in terms of pathological complete response and event-free survival c

Updated on: October 11,2023 24

Perioperative Durvalumab Plus Chemo Yields Responses, EFS Benefit in Resectable NSCLC

September 11, 2023Kyle DohertyThe addition of perioperative durvalumab to neoadjuvant chemotherapy led to a significant improvement in terms of pathological complete response and event-free survival c

Updated on:October 11,2023 24

Iruplinalkib Improves PFS Vs Crizotinib in Locally Advanced or Metastatic ALK+ NSCLC

September 10, 2023Kristi RosaTreatment with iruplinalkib significantly improved progression-free survival and produced a higher objective response rate compared with crizotinib in patients with ALK TK

Updated on: October 11,2023 56

Iruplinalkib Improves PFS Vs Crizotinib in Locally Advanced or Metastatic ALK+ NSCLC

September 10, 2023Kristi RosaTreatment with iruplinalkib significantly improved progression-free survival and produced a higher objective response rate compared with crizotinib in patients with ALK TK

Updated on:October 11,2023 56

Iflinatamab Deruxtecan Elicits Clinical Activity in SCLC

September 10, 2023Jonah FeldmanTreatment with the antibody-drug conjugate ifinatamab deruxtecan in heavily pretreated patients with small cell lung cancer led to promising efficacy and a manageable sa

Updated on: October 11,2023 205

Iflinatamab Deruxtecan Elicits Clinical Activity in SCLC

September 10, 2023Jonah FeldmanTreatment with the antibody-drug conjugate ifinatamab deruxtecan in heavily pretreated patients with small cell lung cancer led to promising efficacy and a manageable sa

Updated on:October 11,2023 205

Intensity of Consolidation Pre-Transplant Shows No Difference in Outcomes in Older AML

September 7, 2023Caroline SeymourNo difference in relapse-free survival or non–relapse mortality was seen with intensive vs non-intensive consolidation chemotherapy regimens prior to allogeneic hemato

Updated on: October 11,2023 258

Intensity of Consolidation Pre-Transplant Shows No Difference in Outcomes in Older AML

September 7, 2023Caroline SeymourNo difference in relapse-free survival or non–relapse mortality was seen with intensive vs non-intensive consolidation chemotherapy regimens prior to allogeneic hemato

Updated on:October 11,2023 258

Neurosurgery: new augmented reality technology helps to complete multiple surgeries

Augmented reality accurate localization, assisting endoscopic cerebral hematoma removal surgeryThe Department of Neurosurgery (Digital/Secure Neurosurgery) of the East Campus accurately localized a

Updated on: October 12,2023 267

Neurosurgery: new augmented reality technology helps to complete multiple surgeries

Augmented reality accurate localization, assisting endoscopic cerebral hematoma removal surgeryThe Department of Neurosurgery (Digital/Secure Neurosurgery) of the East Campus accurately localized a

Updated on:October 12,2023 267

Acalabrutinib Approved in China for Chronic Lymphocytic Leukemia

September 5, 2023Kristi RosaThe National Medical Products Administration in China has approved acalabrutinib for use in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma w

Updated on: October 12,2023 87

Acalabrutinib Approved in China for Chronic Lymphocytic Leukemia

September 5, 2023Kristi RosaThe National Medical Products Administration in China has approved acalabrutinib for use in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma w

Updated on:October 12,2023 87

Divarasib Displays Early-Phase Activity in KRAS G12C–Mutant Solid Tumors

September 5, 2023Kyle DohertyTreatment with the KRAS G12C inhibitor divarasib (formerly GDC-6036)led to durable responses with a tolerable safety profile in patients with a variety of solid tumo

Updated on: October 12,2023 22

Divarasib Displays Early-Phase Activity in KRAS G12C–Mutant Solid Tumors

September 5, 2023Kyle DohertyTreatment with the KRAS G12C inhibitor divarasib (formerly GDC-6036)led to durable responses with a tolerable safety profile in patients with a variety of solid tumo

Updated on:October 12,2023 22

Pembrolizumab With COPDAC-28 Consolidation Increases PET Negativity in Classical Hodgkin Lymphoma

August 29, 2023Kyle DohertyThe addition of pembrolizumab to COPDAC-28 consolidation may augment responses to treatment in pediatric and young adult patients with high-risk classical Hodgkin lymphoma w

Updated on: October 12,2023 202

Pembrolizumab With COPDAC-28 Consolidation Increases PET Negativity in Classical Hodgkin Lymphoma

August 29, 2023Kyle DohertyThe addition of pembrolizumab to COPDAC-28 consolidation may augment responses to treatment in pediatric and young adult patients with high-risk classical Hodgkin lymphoma w

Updated on:October 12,2023 202

EMA Accepts Marketing Application for Odronextamab in R/R DLBCL or Follicular Lymphoma

August 17, 2023Chris RyanThe European Medicines Agency has accepted a marketing authorization application seeking the approval of odronextamab for the treatment of adult patients with relapsed/refract

Updated on: October 12,2023 6

EMA Accepts Marketing Application for Odronextamab in R/R DLBCL or Follicular Lymphoma

August 17, 2023Chris RyanThe European Medicines Agency has accepted a marketing authorization application seeking the approval of odronextamab for the treatment of adult patients with relapsed/refract

Updated on:October 12,2023 6

IBI322 Shows Early Antitumor Efficacy in PD-1/PD-L1–Resistant Classical Hodgkin Lymphoma

August 13, 2023Kristi RosaSingle-agent IBI322 elicited responses with favorable safety in patients with classical Hodgkin lymphoma that had become resistant to anti–PD-1/PD-L1 therapy, according to da

Updated on: October 12,2023 131

IBI322 Shows Early Antitumor Efficacy in PD-1/PD-L1–Resistant Classical Hodgkin Lymphoma

August 13, 2023Kristi RosaSingle-agent IBI322 elicited responses with favorable safety in patients with classical Hodgkin lymphoma that had become resistant to anti–PD-1/PD-L1 therapy, according to da

Updated on:October 12,2023 131

Daratumumab Plus Induction Therapy Reduces Stem Cell Yield in Multiple Myeloma

June 9, 2023Tony Berberabe, MPHThe addition of daratumumab to frontline induction therapy prior to peripheral blood stem cell collection reduced the number of patients with newly diagnosed multiple my

Updated on: October 12,2023 41

Daratumumab Plus Induction Therapy Reduces Stem Cell Yield in Multiple Myeloma

June 9, 2023Tony Berberabe, MPHThe addition of daratumumab to frontline induction therapy prior to peripheral blood stem cell collection reduced the number of patients with newly diagnosed multiple my

Updated on:October 12,2023 41